Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DX-88 inhibitor of human plasma kallikrein regulatory update

FDA placed on clinical hold the Phase II EDEMA2 trial of DYAX's DX-88 recombinant kallikrein inhibitor protein to treat hereditary angioedema (HAE), pending additional

Read the full 245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE